ETX E-therapeutics Plc

e-therapeutics plc  

("e-therapeutics" or "ETX" or the "Company") 

Result of General Meeting

 Matched Bargain Settlement Facility

London, UK, 29 April 2024 - e-therapeutics plc (AIM: ETX), a company integrating computational power and biological data to discover life-transforming RNAi medicines, announces that at the Company's General Meeting held earlier today, all resolutions were duly passed.

Accordingly, pursuant to the passing of Resolution 3, cancellation of admission of the Company's ordinary shares to trading on AIM will become effective at 7.00 a.m. on 9 May 2024. 

The Subscription remains conditional upon regulatory approval, specifically the Subscription by M&G is conditional upon clearance under the National Security and Investment Act 2021 ("NSIA"), by either the Secretary of State: (i) having notified the parties pursuant to the NSIA that no further action will be taken in relation to the Subscription; or (ii) making a final order under the NSIA in respect of the Subscription, the provisions of which would allow completion of the Subscription on terms reasonably satisfactory to M&G. The Richard Griffiths Subscription and the M&G Subscription are each conditional on the occurrence of the other, so the intention is that they will complete at the same time, and further updates will be made on the Company's website at www.etherapeutics.co.uk.

The votes were as follows:

Shareholders are reminded that the last day of dealings in ETX's ordinary shares on AIM will be 8 May 2024.

Matched Bargain Facility

To facilitate future shareholder transactions in the Company's ordinary shares, the Company has appointed JP Jenkins to provide a matched bargain facility, which will be available upon the date of Cancellation.

JP Jenkins ( www.jpjenkins.com ) is a trading name of InfinitX Limited and Appointed Representative of Prosper Capital LLP (FRN453007), which is authorised and regulated by the Financial Conduct Authority. JP Jenkins will operate an electronic off-market dealing facility for the ordinary shares. Under the Matched Bargain Facility, Shareholders or persons wishing to acquire or dispose of Ordinary Shares will be able to leave an indication with JP Jenkins, through their stockbroker (JP Jenkins is unable to deal directly with members of the public), of the number of Ordinary Shares that they are prepared to buy or sell at an agreed price. In the event that JP Jenkins is able to match that order with an opposite sell or buy instruction, it would contact both parties and then effect the bargain.  

Upon Cancellation, full details of the matched bargain facility will be made available to Shareholders on the Company's website at www.etherapeutics.co.uk

Shareholders will continue to be able to hold their shares in uncertificated form (i.e. in CREST) and should check with their existing stockbroker whether they are willing or able to trade in unquoted shares.  

Shareholders should also be aware that the matched bargain facility could be withdrawn at a later date. The provision of a matched bargain facility will be kept under review by the Board and, in determining whether to continue to offer a matched bargain facility, the Company shall consider expected (and communicated) shareholder demand for such a facility as well as the composition of the Company's register of members and the costs to the Company and shareholders.

Unless otherwise defined, capitalised terms used in this announcement shall have the same meaning as set out in the circular sent to shareholders dated 10 April 2024. A copy of the circular is available on the Company's website.

Enquiries 

About e-therapeutics plc 

e-therapeutics plc ("ETX") uniquely combines computation and RNAi to discover and develop life-transforming medicines. ETX's proprietary RNAi chemistry platform, GalOmic™, enables generation of specific, potent, and durable siRNA therapeutics for effective silencing of novel gene targets in hepatocytes. The cutting-edge HepNet™ computational platform allows ETX to discover better medicines faster through generation of novel insights and increased automation across all stages of drug development. HepNet™ encompasses an extensive hepatocyte-specific knowledgebase and a suite of advanced AI-driven approaches which enable identification of novel gene targets, rapid target-indication assessment, and predictive in silico siRNA design. The Company has specialist expertise and a robust position in applying computation to biology. Its computational approaches have been extensively validated through generation of data from pipeline programs and successful drug discovery collaborations with biopharma companies, such as Novo Nordisk, Galapagos NV, and iTeos Therapeutics.

Leveraging the combined capabilities of HepNet™ and GalOmic™, ETX is progressing a therapeutic pipeline of highly differentiated RNAi candidates across a variety of therapeutic areas with high unmet need. The Company has generated positive proof-of-concept data on preclinical assets in metabolic dysfunction-associated steatohepatitis (MASH), dry age-related macular degeneration (dry AMD), haemophilia and, cardiometabolic disease, further validating its computationally enhanced approach to research and development. ETX is currently progressing lead assets ETX-312 for MASH and ETX-407 for dry AMD through IND-enabling studies and towards the clinic.